Do γδ T cells predict osteonecrosis of the jaw?

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 723-727

  Weitzmann, M Neale ^a,b  

^a Affairs Medical Center   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GAMMA DELTA T LYMPHOCYTE; HUMAN; JAW OSTEONECROSIS; NOTE; PREDICTION; BLOOD; FEMALE; IMMUNOLOGY; MALE;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; DIPHOSPHONATES; FEMALE; HUMANS; MALE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA;

EID: 84875319121     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1886     Document Type: Note

References (48)

1. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT., Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999; 265 (1): 144-50.
2. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T., T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000; 408 (6812): 600-5.
3. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N., Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001; 44 (5): 1003-12.
4. Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R., T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res. 2001; 16 (2): 328-37.
5. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL., Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003; 111 (8): 1221-30.
6. Rifas L, Weitzmann MN., A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum. 2009; 60 (11): 3324-35.
7. Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, Sabokbar A., LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum. 2006; 54 (5): 1451-62.
8. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R., Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 2000; 106 (10): 1229-37.
9. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S., Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 1999; 25 (3): 255-9.
10. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL., TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000; 106 (12): 1481-8.
11. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y., Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem. 2001; 276 (1): 563-8.
12. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ., TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002; 143 (3): 1108-18.
13. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen FLT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM., Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999; 402 (6759): 304-9.
14. Brunetti G, Colucci S, Pignataro P, Coricciati M, Mori G, Cirulli N, Zallone A, Grassi FR, Grano M., T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. J Periodontol. 2005; 76 (10): 1675-80.
15. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, Goncalves RB, Valverde P, Dibart S, Li YP, Miranda LA, Ernst CW, Izumi Y, Taubman MA., B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol. 2006; 169 (3): 987-98.
16. Weitzmann MN, Pacifici R., Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006; 116 (5): 1186-94.
17. D'Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, Giribaldi G, Ulliers D, Pescarmona GP, Isaia G., Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis. Bone. 2008; 43 (1): 92-100.
18. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, Pascual V, Hood LE, Clark EA., OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol. 1998; 161 (11): 6113-21.
19. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN., B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007; 109 (9): 3839-48.
20. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, Ofotokun I, Weitzmann MN., Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010; 107 (31): 13848-53.
21. Janeway CA Jr, Bottomly K., Signals and signs for lymphocyte responses. Cell. 1994; 76 (2): 275-85.
22. Starr TK, Jameson SC, Hogquist KA., Positive and negative selection of T cells. Annu Rev Immunol. 2003; 21: 139-76.
23. Pennington DJ, Vermijlen D, Wise EL, Clarke SL, Tigelaar RE, Hayday AC., The integration of conventional and unconventional T cells that characterizes cell-mediated responses. Adv Immunol. 2005; 87: 27-59.
24. Sakaguchi S, Sakaguchi N., Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol. 2005; 24 (3-4): 211-26.
25. Surh CD, Sprent J., Homeostasis of naive and memory T cells. Immunity. 2008; 29 (6): 848-62.
26. Zheng Y, Zha Y, Gajewski TF., Molecular regulation of T-cell anergy. EMBO Rep. 2008; 9 (1): 50-5.
27. Smith-Garvin JE, Koretzky GA, Jordan MS., T cell activation. Annu Rev Immunol. 2009; 27: 591-619.
28. Hayday AC., Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009; 31 (2): 184-96.
29. Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, Kaplan DH, Hayday AC, Girardi M., Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol. 2008; 9 (2): 146-54.
30. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR., Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995; 375 (6527): 155-8.
31. Pang DJ, Neves JF, Sumaria N, Pennington DJ., Understanding the complexity of gammadelta T-cell subsets in mouse and human. Immunology. 2012; 136 (3): 283-90.
32. Kunzmann V, Bauer E, Wilhelm M., Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999; 340 (9): 737-8.
33. Rossini M, Adami S, Viapiana O, Fracassi E, Ortolani R, Vella A, Zanotti R, Tripi G, Idolazzi L, Gatti D., Long-term effects of amino-bisphosphonates on circulating gammadelta T cells. Calcif Tissue Int. 2012; 91 (6): 395-9.
34. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G., Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003; 197 (2): 163-8.
35. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K., Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2009; 144 (2): 245-50.
36. Miyagawa F, Tanaka Y, Yamashita S, Minato N., Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol. 2001; 166 (9): 5508-14.
37. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E., Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate- associated osteonecrosis of the jaw?. A prospective clinical study. Clin Oral Investig. 2010; 14 (3): 311-7.
38. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E., Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22 (10): 1479-91.
39. Kalyan S, Quabius ES, Wiltfang J, Mönig H, Kabelitz D., Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J Bone Miner Res. 2013; 28: 728-35.
40. Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudiere L, Costagliola D, Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS. 2006; 20 (12): 1627-35.
41. Shetty K., HIV patients are at higher risk for osteonecrosis in the oral cavity. HIV Clin. 2008; 20 (1): 6-8.
42. Enders PJ, Yin C, Martini F, Evans PS, Propp N, Poccia F, Pauza CD., HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses. 2003; 19 (1): 21-9.
43. Ofotokun I, Weitzmann MN., HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010; 17 (6): 523-9.
44. Ofotokun I, Weitzmann MN., HIV and bone metabolism. Discov Med. 2011; 11 (60): 385-93.
45. Mawardi H, Giro G, Kajiya M, Ohta K, Almazrooa S, Alshwaimi E, Woo SB, Nishimura I, Kawai T., A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J Dent Res. 2011; 90 (11): 1339-45.
46. Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB., RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?. Support Care Cancer. 2011; 19 (12): 2035-40.
47. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L., A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997; 390 (6656): 175-9.
48. Roberts NA, White AJ, Jenkinson WE, Turchinovich G, Nakamura K, Withers DR, McConnell FM, Desanti GE, Benezech C, Parnell SM, Cunningham AF, Paolino M, Penninger JM, Simon AK, Nitta T, Ohigashi I, Takahama Y, Caamano JH, Hayday AC, Lane PJ, Jenkinson EJ, Anderson G., Rank signaling links the development of invariant gammadelta T cell progenitors and Aire(+) medullary epithelium. Immunity. 2012; 36 (3): 427-37.